Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01527682|
Recruitment Status : Unknown
Verified August 2015 by Luciano Quaranta MD, Azienda Ospedaliera Spedali Civili di Brescia.
Recruitment status was: Active, not recruiting
First Posted : February 7, 2012
Last Update Posted : September 1, 2015
The study will assess the ocular hypotensive effect of latanoprost and dorzolamide in a selected sample of patients affected by primary Pediatric Glaucoma (PG), refractory to surgical procedures. Safety will be assessed, too.In the first version of the protocol 96 eyes were forecasted to complete the enrolment. The protocol was then amended and now to complete the study 68 eyes should be included.
|Condition or disease||Intervention/treatment||Phase|
|Childhood Glaucoma||Drug: Latanoprost, Dorzolamide||Phase 2|
Single arm, prospective, experimental study. Due to ethical reasons and in order to adhere as much as possible to current clinical practice, the presence of a control arm is not planned. Due to the non-comparative nature of the study, no blinding of treatment is planned.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||69 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy and Safety of Prostaglandin Analogue and Carbonic Anhydrase Inhibitor for the Treatment of Pediatric Glaucoma|
|Study Start Date :||July 2009|
|Estimated Primary Completion Date :||January 2017|
|Estimated Study Completion Date :||July 2017|
According to IOP assessment, the eye will receive Latanoprost, Dorzolamide or both.
Drug: Latanoprost, Dorzolamide
- percentage of "responder" [ Time Frame: 3 years ]defined as those eyes in which the decrease of intraocular pressure (IOP) of at least 20% with respect to baseline assessment will be achieved and maintained during the 3-year period of study duration
- Time to treatment failure (TTF) [ Time Frame: 3 years ]calculated as the time from the date of baseline visit to the date in which the medical treatment will be stopped, since IOP control will be considered not satisfactory
- Incidence of adverse events (AEs) [ Time Frame: 3 years ]The occurrence of the following events will be monitored: growth of the eyelashes (hypertrichosis), changes iris colour, corneal epitheliopathy, allergic conjunctivitis, increase of central corneal thickness, non-serious and serious adverse event occurrence.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01527682
|Azienda Ospedaliera Spedali Civili di Brescia|
|Brescia, Italy, 25123|
|A.O. Universitaria " Policlinico Vittorio Emanuele" P.O. Rodolico|
|Catania, Italy, 95123|
|Principal Investigator:||Luciano Quaranta, MD||Università di Brescia, Spedali Civili di Brescia|